Role of Thrombopoietin Receptor Agonists in Inherited Thrombocytopenia [PDF]
International Journal of Molecular Sciences, 2021 In the last decade, improvements in genetic testing have revolutionized the molecular diagnosis of inherited thrombocytopenias (ITs), increasing the spectrum of knowledge of these rare, complex and heterogeneous disorders. In contrast, the therapeutic management of ITs has not evolved in the same way.
JOSÉ Maria Bastida +2 more
exaly +5 more sources
Use of thrombopoietin receptor agonists in childhood immune thrombocytopenia [PDF]
Frontiers in Pediatrics, 2015 Most children with immune thrombocytopenia (ITP) will have spontaneous remission regardless of therapy, while about 20% will go on to have chronic ITP.
Angelica Maria Garzon +2 more
doaj +5 more sources
Thrombopoietin Receptor Agonists in Post-Hematopoietic Cell Transplantation Complicated by Prolonged Thrombocytopenia: A Comprehensive Review [PDF]
ImmunoTargets and TherapyAbdelrahman Elsayed,1 Basant Elsayed,1 Mohamed Elmarasi,1 Ahmed Adel Elsabagh,1 Engy Elsayed,2 Ibrahim Elmakaty,1 Mohamed Yassin2,3 1Department of Medical Education, Hamad Medical Corporation, Doha, Qatar; 2College of Medicine, Qatar University, Doha ...
Elsayed A +6 more
doaj +4 more sources
Should thrombopoietin receptor agonists be used for chemotherapy-induced thrombocytopenia? [PDF]
Research and Practice in Thrombosis and HaemostasisChemotherapy-induced thrombocytopenia (CIT) is a common complication of cancer therapy for solid tumors that results in increased bleeding risk and chemotherapy dose reductions, treatment delays, and agent discontinuation.
Hanny Al-Samkari
doaj +2 more sources
Thrombopoietin receptor agonists: ten years later
Haematologica, 2019 The two thrombopoietin receptor agonists (TPO-RA), eltrombopag and romiplostim, were licensed in the US for treatment of immune thrombocytopenia (ITP) in 2008 and, since then, their use has progressively increased around the world; they are currently ...
Waleed Ghanima +4 more
doaj +3 more sources
Knowledge map of thrombopoietin receptor agonists: A bibliometric analysis [PDF]
HeliyonBackground: Thrombopoietin receptor agonists (TPO-RAs) have been widely used to treat thrombocytopenia, however, a scientometric profile of TPO-RAs research is lacking.
Rong Hu, Songbin Guo, Min Liu
doaj +2 more sources
Impact of Thrombopoietin Receptor Agonists on Pathophysiology of Pediatric Immune Thrombocytopenia [PDF]
Current Issues in Molecular BiologyImmune thrombocytopenia (ITP) in pediatric patients is a common cause of isolated thrombocytopenia. Various pathophysiological mechanisms are implicated in ITP pathogenesis, including the production of autoantibodies against components of platelets (PLTs)
Paschalis Evangelidis +3 more
doaj +2 more sources
Optimal use of thrombopoietin receptor agonists in immune thrombocytopenia [PDF]
Therapeutic Advances in Hematology, 2019 The thrombopoietin receptor agonists (TPO-RAs) are a class of platelet growth factors commonly used to treat immune thrombocytopenia (ITP). There are three agents that have been investigated for the treatment of chronic ITP: the peptide agent romiplostim
Hanny Al-Samkari, David J. Kuter
doaj +3 more sources
Therapeutic Advances in Hematology, 2021 Introduction: In patients with primary immune thrombocytopenia (ITP), a short course of steroids is routinely given as first-line therapy. However, the response is often transient and additional therapy is usually needed. Thrombopoietin receptor agonists
Monica Carpenedo +14 more
doaj +2 more sources
Thrombopoietin Receptor Agonists for Thrombocytopenia in Pediatric Hematologic Malignancies. [PDF]
Pediatr Blood CancerABSTRACTBackgroundThrombopoietin receptor agonists (TPO‐RAs) have demonstrated efficacy in treating clinically significant thrombocytopenia, including chemotherapy‐induced thrombocytopenia in adults. However, data regarding their safety and efficacy in pediatric, adolescents, and young adult (AYA) patients with hematologic malignancies are limited ...
Marinoff AE +12 more
europepmc +3 more sources